Correlation Between Altered Gut Microbiota and Elevated Inflammation Markers in Patients with Crohn's Disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 1

PMID 36045690

Authors

Jun Hu

Sijing Cheng

Jiayin Yao

Xutao Lin

Yichen Li

Wenxia Wang

Jingrong Weng

Yifeng Zou

Lixin Zhu

Min Zhi

Affiliations

Soon will be listed here.

Abstract

Prior studies reported inconsistent results on the altered gut microbial composition in patients with Crohn's disease (CD), likely under the influences of many confounding factors including genetic, life style and environmental variations among different study cohorts. This study aims to examine the gut microbiota of CD patients with particular efforts to minimize the impact of the confounding factors. For this purpose, the healthy relatives of the patients were enrolled as control subjects so that the paired study subjects may have similar genetic background, dietary habits, and household environment. The fecal microbiota of the study subjects were examined by 16S rRNA sequencing. After the identification of the differential bacterial genera, multivariate regression analysis was performed to adjust the results for the impact of confounding factors. We found that the microbiota of the CD patients were featured with reduced short chain fatty acid (SCFA) producing bacteria and elevated opportunistic pathogen . Correlation analysis indicated that the elevation in and the reduction in SCFA-producing bacteria usually occur simultaneously. These differential genera exhibited a high capacity in distinguishing between CD and healthy controls achieving an area under curve of 0.89, and were correlated with the changes in inflammation related blood biochemical markers. Consistent with the reduction in SCFA-producing bacteria in CD, metabolomics analysis revealed decreased blood level of SCFAs in the patients. The differential genera identified in this study demonstrated outstanding capability to serve as diagnosis markers for CD and are potential targets for intervention.

Citing Articles

The Use of Gut Organoids: To Study the Physiology and Disease of the Gut Microbiota.

Deng Y, Yuan X, Lu X, Wu J, Luo C, Zhang T J Cell Mol Med. 2025; 29(4):e70330.

PMID: 39968926 PMC: 11836903. DOI: 10.1111/jcmm.70330.

016 Alleviates Mice Colitis by Modulating Oxidative Stress, Gut Microbiota, and Microbial Metabolism.

Pan H, Yang S, Kulyar M, Ma H, Li K, Zhang L Nutrients. 2025; 17(3).

PMID: 39940311 PMC: 11820689. DOI: 10.3390/nu17030452.

Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein.

Britton G, Mogno I, Chen-Liaw A, Plitt T, Helmus D, Bongers G bioRxiv. 2025; .

PMID: 39868147 PMC: 11761010. DOI: 10.1101/2025.01.14.633015.

The involvement of oral bacteria in inflammatory bowel disease.

Xiang B, Hu J, Zhang M, Zhi M Gastroenterol Rep (Oxf). 2024; 12:goae076.

PMID: 39188957 PMC: 11346772. DOI: 10.1093/gastro/goae076.

Chemical Profile and In Vitro Gut Microbiota Modulation of Wild Edible Mushroom Fruiting Body at Different Maturity Stages.

Kaewsaen R, Wichienchot S, Thayanukul P, Charoensiddhi S, Chanput W Nutrients. 2024; 16(15).

PMID: 39125432 PMC: 11313837. DOI: 10.3390/nu16152553.

References

Fachi J, de Souza Felipe J, Pral L, da Silva B, Correa R, de Andrade M . Butyrate Protects Mice from Clostridium difficile-Induced Colitis through an HIF-1-Dependent Mechanism. Cell Rep. 2019; 27(3):750-761.e7. DOI: 10.1016/j.celrep.2019.03.054. View

Sharma A, Yang W, Ochani M, Wang P . Mitigation of sepsis-induced inflammatory responses and organ injury through targeting Wnt/β-catenin signaling. Sci Rep. 2017; 7(1):9235. PMC: 5569053. DOI: 10.1038/s41598-017-08711-6. View

Froman G, Switalski L, Faris A, Wadstrom T, Hook M . Binding of Escherichia coli to fibronectin. A mechanism of tissue adherence. J Biol Chem. 1984; 259(23):14899-905. View

Beeckmans D, Farre R, Riethorst D, Keita A, Augustijns P, Soderholm J . Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia. Neurogastroenterol Motil. 2020; 32(5):e13788. DOI: 10.1111/nmo.13788. View

Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran L, Gratadoux J . Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105(43):16731-6. PMC: 2575488. DOI: 10.1073/pnas.0804812105. View

Armstrong H, Alipour M, Valcheva R, Bording-Jorgensen M, Jovel J, Zaidi D . Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases. Microbiome. 2019; 7(1):1. PMC: 6317230. DOI: 10.1186/s40168-018-0604-3. View

Schirmer M, Garner A, Vlamakis H, Xavier R . Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol. 2019; 17(8):497-511. PMC: 6759048. DOI: 10.1038/s41579-019-0213-6. View

Ioannou P . Infections in Humans: A Systematic Review. Trop Med Infect Dis. 2019; 4(1). PMC: 6473853. DOI: 10.3390/tropicalmed4010017. View

Yang Q, Liu J, Wang X, Robinson K, Whitmore M, Stewart S . Identification of an Intestinal Microbiota Signature Associated With the Severity of Necrotic Enteritis. Front Microbiol. 2021; 12:703693. PMC: 8418326. DOI: 10.3389/fmicb.2021.703693. View

10.

Roda G, Ng S, Kotze P, Argollo M, Panaccione R, Spinelli A . Crohn's disease. Nat Rev Dis Primers. 2020; 6(1):22. DOI: 10.1038/s41572-020-0156-2. View

11.

Nardone G, Compare D, Rocco A . A microbiota-centric view of diseases of the upper gastrointestinal tract. Lancet Gastroenterol Hepatol. 2017; 2(4):298-312. DOI: 10.1016/S2468-1253(16)30108-X. View

12.

Keewan E, Naser S . Notch-1 Signaling Modulates Macrophage Polarization and Immune Defense against Infection in Inflammatory Diseases. Microorganisms. 2020; 8(7). PMC: 7409363. DOI: 10.3390/microorganisms8071006. View

13.

Gevers D, Kugathasan S, Denson L, Vazquez-Baeza Y, Van Treuren W, Ren B . The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014; 15(3):382-392. PMC: 4059512. DOI: 10.1016/j.chom.2014.02.005. View

14.

Orczyk-Pawilowicz M, Hirnle L, Berghausen-Mazur M, Katnik-Prastowska I . Terminal glycotope expression on milk fibronectin differs from plasma fibronectin and changes over lactation. Clin Biochem. 2014; 48(3):167-73. DOI: 10.1016/j.clinbiochem.2014.11.011. View

15.

Jensen S, Paerregaard S, Brandum E, Jorgensen A, Hjorto G, Jensen B . Rewiring host-microbe interactions and barrier function during gastrointestinal inflammation. Gastroenterol Rep (Oxf). 2022; 10(1):goac008. PMC: 8915887. DOI: 10.1093/gastro/goac008. View

16.

Cheng S, Hu J, Wu X, Pan J, Jiao N, Li Y . Altered gut microbiome in FUT2 loss-of-function mutants in support of personalized medicine for inflammatory bowel diseases. J Genet Genomics. 2021; 48(9):771-780. DOI: 10.1016/j.jgg.2021.08.003. View

17.

Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P . Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013; 504(7480):451-5. PMC: 3869884. DOI: 10.1038/nature12726. View

18.

Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S . Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?. EBioMedicine. 2021; 66:103293. PMC: 8047503. DOI: 10.1016/j.ebiom.2021.103293. View

19.

Bose T, Venkatesh K, Mande S . Investigating host-bacterial interactions among enteric pathogens. BMC Genomics. 2019; 20(1):1022. PMC: 6935094. DOI: 10.1186/s12864-019-6398-2. View

20.

Zhu L, Liu W, Alkhouri R, Baker R, Bard J, Quigley E . Structural changes in the gut microbiome of constipated patients. Physiol Genomics. 2014; 46(18):679-86. DOI: 10.1152/physiolgenomics.00082.2014. View